1. Repositório Institucional da UFMG
  2. Publicações Científicas e Culturais
  3. Artigo de Periódico
Please use this identifier to cite or link to this item: http://hdl.handle.net/1843/56040
Full metadata record
DC FieldValueLanguage
dc.creatorIsamara Simas de Oliveirapt_BR
dc.creatorAlessandro Fernandes Guimarãespt_BR
dc.creatorGabriela Rafael Arantes Pêgaspt_BR
dc.creatorCarla Jorge Machadopt_BR
dc.creatorGiovanni Dantas Cassalipt_BR
dc.creatorPaulo Crossarapt_BR
dc.creatorFlávio Barbosa Nunespt_BR
dc.creatorHelena Maria Gonçalves Beckerpt_BR
dc.creatorRoberto Eustáquio Santos Guimarãespt_BR
dc.date.accessioned2023-07-10T19:54:31Z-
dc.date.available2023-07-10T19:54:31Z-
dc.date.issued2020-07-10-
dc.citation.volume58pt_BR
dc.citation.issue6pt_BR
dc.citation.spage610pt_BR
dc.citation.epage617pt_BR
dc.identifier.doi10.4193/Rhin20.071pt_BR
dc.identifier.issn03000729pt_BR
dc.identifier.urihttp://hdl.handle.net/1843/56040-
dc.description.resumoBackground: Chronic eosinophilic rhinosinusitis with nasal polyps (CRSwNP eosinophilic) is characterised by the formation of benign and bilateral nasal polyps. We aimed to compare the effectiveness of azithromycin as an immunomodulator with the use of a placebo in patients presenting with CRSwNP concomitant with asthma and aspirin intolerance after 3 months of treatment and at a 1-year follow-up.Methodology: We performed a randomised, double-blind, placebo-controlled trial. Patients received 500 mg azithromycin orally three times/week for 12 weeks. Improvement was evaluated by staging, the Sino-Nasal Outcome Test (SNOT-22), and nasal polyp biopsy. Data collected at pretreatment and 3 months posttreatment were compared. Quality of life was evaluated at the 1-year follow-up. Results: Twenty-seven and 21 patients were treated with azithromycin and a placebo, respectively. The medication was well tolerated overall. Twenty patients (74%) in the azithromycin group and three patients (14%) in the placebo group were not referred for surgery at the end of the 3-month treatment. Regarding subjective improvement, there was a median decrease only in the azithromycin group, and the between-group difference was significant. SNOT-22 improvement was maintained in the azithromycin group at the 1-year follow-up. Conclusions: Azithromycin could be considered a therapeutic option for patients presenting with CRSwNP concomitant with asthma and aspirin intolerance.pt_BR
dc.format.mimetypepdfpt_BR
dc.languageporpt_BR
dc.publisherUniversidade Federal de Minas Geraispt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.departmentICB - DEPARTAMENTO DE PATOLOGIApt_BR
dc.publisher.departmentMED - DEPARTAMENTO DE MEDICINA PREVENTIVA SOCIALpt_BR
dc.publisher.departmentMED - DEPARTAMENTO DE OFTALMOLOGIA E OTORRINOLARINGOLOGIApt_BR
dc.publisher.initialsUFMGpt_BR
dc.relation.ispartofRhinology-
dc.rightsAcesso Abertopt_BR
dc.subjectAspirinpt_BR
dc.subjectAzithromycinpt_BR
dc.subjectEndoscopypt_BR
dc.subjectEosinophilspt_BR
dc.subjectNasal polyposispt_BR
dc.subject.otherAspirinapt_BR
dc.subject.otherAzitromicinapt_BR
dc.subject.otherEndoscopiapt_BR
dc.subject.otherEosinófilospt_BR
dc.subject.otherPólipos Nasaispt_BR
dc.titleAzitromycin for chronic eosihophilic rhinosinusitis with nasal polyp: a placebo-controlled trialpt_BR
dc.typeArtigo de Periódicopt_BR
dc.url.externahttps://www.rhinologyjournal.com/Abstract.php?id=2662pt_BR
Appears in Collections:Artigo de Periódico

Files in This Item:
File Description SizeFormat 
Azithromycin for chronic eosinophilic rhinosinusitis with pdfa.pdf173.34 kBAdobe PDFView/Open
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.